A two-dimensional nanothrombolytic agent and its preparation method and application
By coating two-dimensional nanothrombolytic agents with fibrinogen and thrombolytic enzymes on two-dimensional hydrogen silene nanosheets, the problems of poor targeting of existing thrombolytic agents, large side effects and prone to recurrence of thromboplasms are solved, and the effect of continuous thrombolysis and reducing bleeding risk is achieved.
CN115869386BActive Publication Date: 2025-03-18SHANGHAI TENTH PEOPLES HOSPITAL
2 Cites 0 Cited by
Patent Information
- Application Number
- CN202211656703.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-12-22
- Publication Date
- 2025-03-18
- Estimated Expiration
- 2042-12-22
AI Technical Summary
Technical Problem
Existing thrombolytic agents have poor targeting, large side effects and prone to recurrence of thromboplasm when treating thromboplasm, making it difficult to achieve continuous thrombolysis and reduce the risk of systemic bleeding.
Method used
A two-dimensional nanothrombolytic agent was developed to achieve thrombo-targeted delivery of thrombolytic enzymes and hydrogen-mediated regulation of the thrombomic microenvironment by coating fibrinogen and thrombolytic enzymes on two-dimensional hydrogen silene nanosheets.
Benefits of technology
It improves the half-life and specificity of thrombolytic enzymes, achieves continuous thrombolytic effect, reduces the risk of systemic bleeding, and prevents thrombus recurrence through hydrogen therapy.
✦ Generated by Eureka AI based on patent content.
Abstract
The present invention discloses a two-dimensional nanothrombolytic agent and a preparation method and application thereof, wherein the two-dimensional nanothrombolytic agent is specifically composed of two-dimensional hydrogen silene nanosheets, fibrinogen and thrombolytic enzyme. The two-dimensional nanothrombolytic agent of the present invention can remain stable in the blood circulation, and after reaching the thrombus site, the fibrinogen is cut into insoluble fibrin, thereby promoting the deposition of the nanothrombolytic agent at the thrombus site, and slowly releasing the thrombolytic enzyme and hydrogen to achieve thrombolysis and anti-inflammation. The nanothrombolytic agent provided by the present invention can not only increase the in vivo circulation time and thrombus targeting of the thrombolytic enzyme, play a better thrombolytic effect and reduce the risk of bleeding, but also can achieve active oxygen scavenging and endothelial tissue repair through hydrogen treatment, regulate the thrombus microenvironment, prevent thrombus recurrence, and play a combined anti-thrombotic effect.
Need to check novelty before this filing date? Find Prior Art